{"id":"risperidone-tablets","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Weight gain"},{"rate":"20-30","effect":"Sedation"},{"rate":"10-20","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"10-20","effect":"Prolactin elevation (galactorrhea, amenorrhea)"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"15-25","effect":"Metabolic syndrome"},{"rate":"10-15","effect":"Akathisia"}]},"_chembl":{"chemblId":"CHEMBL85","moleculeType":"Small molecule","molecularWeight":"410.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. This dual antagonism distinguishes it from typical antipsychotics and is associated with a lower risk of extrapyramidal side effects.","oneSentence":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:19.890Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder (acute mania and maintenance)"},{"name":"Irritability associated with autism spectrum disorder"},{"name":"Behavioral disturbances in dementia"}]},"trialDetails":[{"nctId":"NCT07477301","phase":"PHASE2","title":"Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and Inflammation in Schizophrenia","status":"COMPLETED","sponsor":"Hasanuddin University","startDate":"2024-12-01","conditions":"Schizophrenia, Cognitive Dysfunction, Inflamation","enrollment":46},{"nctId":"NCT04624243","phase":"PHASE2","title":"Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-15","conditions":"Schizophrenia","enrollment":499},{"nctId":"NCT04105231","phase":"PHASE2","title":"Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lone Baandrup","startDate":"2021-06-01","conditions":"Dual Diagnosis","enrollment":64},{"nctId":"NCT02469155","phase":"PHASE3","title":"A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2015-06","conditions":"Schizophrenia","enrollment":696},{"nctId":"NCT04478838","phase":"PHASE4","title":"\"Extended\" (Alternate Day) Antipsychotic Dosing","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2022-06-06","conditions":"Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy","enrollment":120},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03713658","phase":"PHASE4","title":"A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-18","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT06878833","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder","status":"WITHDRAWN","sponsor":"Lyndra Inc.","startDate":"2025-04-18","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":""},{"nctId":"NCT04201834","phase":"PHASE2","title":"Risperidone for the Treatment of Huntington's Disease Involuntary Movements","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2020-08-13","conditions":"Huntington Disease, Chorea","enrollment":6},{"nctId":"NCT06838104","phase":"NA","title":"Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lahore General Hospital","startDate":"2024-12-05","conditions":"Schizophrenia Disorders, Psychotic Disorder","enrollment":76},{"nctId":"NCT05779241","phase":"PHASE3","title":"Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005","status":"COMPLETED","sponsor":"Lyndra Inc.","startDate":"2023-04-13","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":83},{"nctId":"NCT03818256","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2019-12-04","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":71},{"nctId":"NCT05401019","phase":"PHASE2","title":"Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)","status":"WITHDRAWN","sponsor":"Clinical Academic Center (2CA-Braga)","startDate":"2022-06","conditions":"Obsessive-Compulsive Disorder","enrollment":""},{"nctId":"NCT03055338","phase":"PHASE2","title":"An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-08","conditions":"Schizophrenia, Acute Episode","enrollment":224},{"nctId":"NCT00830349","phase":"PHASE1","title":"Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-06","conditions":"Healthy","enrollment":30},{"nctId":"NCT00829894","phase":"PHASE1","title":"Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT04529226","phase":"PHASE2","title":"Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-11-26","conditions":"Psychosis, Intellectual Disability","enrollment":75},{"nctId":"NCT05491720","phase":"PHASE1","title":"Electrical Brain Stimulation and Pharmacological Treatments in Autism Spectrum Disorder","status":"COMPLETED","sponsor":"The National Brain Mapping Laboratory (NBML)","startDate":"2020-08-15","conditions":"Autism Spectrum Disorder","enrollment":45},{"nctId":"NCT00202007","phase":"PHASE2","title":"Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2005-02","conditions":"Schizophrenia","enrollment":240},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT04567524","phase":"PHASE2","title":"A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules","status":"COMPLETED","sponsor":"Lyndra Inc.","startDate":"2020-08-13","conditions":"Schizophrenia Schizoaffective","enrollment":34},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT04094207","phase":"PHASE1, PHASE2","title":"Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-01-01","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT05179525","phase":"PHASE1","title":"Comparative Bioavailability of Risperidone.","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2021-03-09","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT04071639","phase":"PHASE1","title":"Symptomatic Therapy for Patients With Huntington's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-03-12","conditions":"Huntington Disease","enrollment":60},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT04446234","phase":"PHASE4","title":"Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2021-05","conditions":"Schizophrenia","enrollment":350},{"nctId":"NCT03568500","phase":"PHASE4","title":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-21","conditions":"Schizophrenia, Schizoaffective Disorder, First Episode Psychosis","enrollment":44},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03007303","phase":"","title":"The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients","status":"UNKNOWN","sponsor":"Dalian Seventh People's Hospital","startDate":"2016-06","conditions":"Schizophrenia, Micrognathia","enrollment":30},{"nctId":"NCT03230864","phase":"PHASE3","title":"Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2017-07-20","conditions":"Treatment-resistant Schizophrenia","enrollment":119},{"nctId":"NCT02717195","phase":"PHASE3","title":"Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-04","conditions":"Schizophrenia","enrollment":1098},{"nctId":"NCT02002832","phase":"PHASE3","title":"A Clinical Trial of Lurasidone in Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2013-12","conditions":"Schizophrenia","enrollment":388},{"nctId":"NCT00573287","phase":"NA","title":"First Episode Schizophrenia and Cannabis-Related Disorder Study","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2006-06","conditions":"Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia","enrollment":14},{"nctId":"NCT02926976","phase":"NA","title":"The Optimal Treatment for Treatment-resistant Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2016-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT03730857","phase":"PHASE1","title":"Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics","status":"COMPLETED","sponsor":"Calo Psychiatric Center","startDate":"2008-01","conditions":"Schizophrenia","enrollment":111},{"nctId":"NCT03790085","phase":"EARLY_PHASE1","title":"Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals","status":"UNKNOWN","sponsor":"Tianjin Medical University General Hospital","startDate":"2018-09-01","conditions":"Schizophrenia, Major Depressive Disorder, Anxiety Disorders","enrollment":2700},{"nctId":"NCT01516424","phase":"PHASE3","title":"Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2012-02","conditions":"Schizophrenia","enrollment":267},{"nctId":"NCT02109562","phase":"PHASE3","title":"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2014-04","conditions":"Schizophrenia","enrollment":354},{"nctId":"NCT01677377","phase":"PHASE2","title":"Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-08","conditions":"Schizophrenia","enrollment":45},{"nctId":"NCT01175135","phase":"PHASE2","title":"An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-10","conditions":"Schizophrenia","enrollment":259},{"nctId":"NCT02051387","phase":"PHASE1","title":"Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2013-01","conditions":"Schizophrenia","enrollment":74},{"nctId":"NCT03220867","phase":"PHASE1","title":"Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants","status":"WITHDRAWN","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2017-12-11","conditions":"Healthy","enrollment":""},{"nctId":"NCT00939497","phase":"PHASE1","title":"Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00939926","phase":"PHASE1","title":"Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00269035","phase":"PHASE1","title":"SPECT Study With SB-773812 In Schizophrenic Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-21","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT00385801","phase":"PHASE2","title":"Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-09","conditions":"Cocaine Dependence","enrollment":31},{"nctId":"NCT00158028","phase":"NA","title":"Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"1995-11","conditions":"Schizotypal Personality Disorder","enrollment":25},{"nctId":"NCT02758067","phase":"PHASE3","title":"Comparison of the Effectiveness of Brexpiprazole With That of Risperidone","status":"WITHDRAWN","sponsor":"H. Lundbeck A/S","startDate":"2016-06","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT01670071","phase":"PHASE4","title":"A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia","status":"TERMINATED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2013-01","conditions":"Schizophrenia","enrollment":17},{"nctId":"NCT00272025","phase":"PHASE1","title":"Treatment Resistant Bipolar Depression","status":"TERMINATED","sponsor":"Queen's University","startDate":"2006-10","conditions":"Bipolar Depression","enrollment":1},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT01822730","phase":"PHASE4","title":"A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis","status":"COMPLETED","sponsor":"Wei Hao","startDate":"2013-02","conditions":"Methamphetamine Dependence","enrollment":120},{"nctId":"NCT00099983","phase":"PHASE2","title":"Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2006-10","conditions":"Stress Disorders, Post-Traumatic","enrollment":296},{"nctId":"NCT01592201","phase":"PHASE4","title":"A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug","status":"TERMINATED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2012-07","conditions":"Schizophrenia","enrollment":13},{"nctId":"NCT00589914","phase":"PHASE3","title":"Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-03","conditions":"Schizophrenia","enrollment":1221},{"nctId":"NCT02137616","phase":"NA","title":"Antipsychotic to Treat Psychosis Syndrome","status":"UNKNOWN","sponsor":"Central South University","startDate":"2012-06","conditions":"Psychotic Disorders","enrollment":300},{"nctId":"NCT00216476","phase":"PHASE3","title":"A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2004-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":753},{"nctId":"NCT00294008","phase":"","title":"A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2004-12","conditions":"Schizophrenia, Tranquilizing Agents, Mental Disorders","enrollment":230},{"nctId":"NCT00910780","phase":"PHASE2, PHASE3","title":"Metabolic Effects of Antipsychotic Substitution in Children","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2009-11","conditions":"Diabetes","enrollment":""},{"nctId":"NCT00992407","phase":"PHASE4","title":"An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2007-12","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00934635","phase":"PHASE4","title":"A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls","status":"TERMINATED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2009-09","conditions":"Schizophrenia","enrollment":2},{"nctId":"NCT02012049","phase":"PHASE1","title":"Bioequivalence Test for Risperdal 2mg of Janssen Korea","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2009-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT00508157","phase":"PHASE4","title":"A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Metabolic Syndrome, Schizophrenia","enrollment":125},{"nctId":"NCT00857818","phase":"PHASE3","title":"Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-04","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder","enrollment":64},{"nctId":"NCT01010776","phase":"PHASE4","title":"A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2008-02","conditions":"Schizophrenia","enrollment":223},{"nctId":"NCT00237913","phase":"PHASE3","title":"Schizophrenia Trial of Aripiprazole","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":700},{"nctId":"NCT00232687","phase":"PHASE4","title":"A Switch Study of BMS-337039 in Schizophrenic Out-patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-06","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT00325689","phase":"PHASE4","title":"Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-07","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":323},{"nctId":"NCT00604279","phase":"PHASE3","title":"A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2008-01","conditions":"Schizophrenia","enrollment":452},{"nctId":"NCT00975611","phase":"PHASE4","title":"Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation","status":"TERMINATED","sponsor":"David C. Henderson, MD","startDate":"2009-10","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":6},{"nctId":"NCT01607762","phase":"PHASE1","title":"A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-02","conditions":"Healthy","enrollment":31},{"nctId":"NCT01207414","phase":"PHASE4","title":"Switching to Iloperidone From Other Antipsychotics in Schizophrenia","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-08","conditions":"Schizophrenia","enrollment":501},{"nctId":"NCT01129674","phase":"PHASE2, PHASE3","title":"A Long-Term, Open-Label, Study on Schizophrenia","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Schizophrenia","enrollment":1210},{"nctId":"NCT01722201","phase":"PHASE1","title":"Bioequivalence Study of Risperidone Tablet 1 mg Under Fasting Condition","status":"COMPLETED","sponsor":"IPCA Laboratories Ltd.","startDate":"2012-06","conditions":"Fasting","enrollment":48},{"nctId":"NCT00600756","phase":"PHASE3","title":"Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Schizophrenic Disorders","enrollment":798},{"nctId":"NCT01423487","phase":"NA","title":"Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea","status":"WITHDRAWN","sponsor":"Central South University","startDate":"2011-08","conditions":"Weight Gain, Amenorrhea","enrollment":""},{"nctId":"NCT00086112","phase":"PHASE3","title":"Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Anxiety Disorders","enrollment":301},{"nctId":"NCT01618760","phase":"PHASE1","title":"Bioequivalence Study of Risperidone Tablet 1 mg Under Fed Condition","status":"COMPLETED","sponsor":"IPCA Laboratories Ltd.","startDate":"2012-05","conditions":"Fed","enrollment":48},{"nctId":"NCT00856583","phase":"PHASE3","title":"Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2002-07","conditions":"Schizophrenia","enrollment":9809},{"nctId":"NCT00986336","phase":"PHASE1","title":"A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-02","conditions":"Bipolar Disorder","enrollment":56},{"nctId":"NCT00086320","phase":"PHASE3","title":"A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-03","conditions":"Schizophrenia","enrollment":111},{"nctId":"NCT00236457","phase":"PHASE3","title":"A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2000-11","conditions":"Schizophrenia, Psychotic Disorders","enrollment":629},{"nctId":"NCT00236548","phase":"PHASE3","title":"Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Schizophrenia, Psychotic Disorders","enrollment":1},{"nctId":"NCT00240708","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2004-06","conditions":"Schizophrenia","enrollment":205},{"nctId":"NCT00257075","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2000-12","conditions":"Bipolar Disorders, Manic Episode","enrollment":267},{"nctId":"NCT00249236","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-03","conditions":"Bipolar Disorder, Manic Episode","enrollment":291},{"nctId":"NCT00249223","phase":"PHASE3","title":"A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2000-01","conditions":"Schizophrenia, Psychotic Disorders","enrollment":641},{"nctId":"NCT00761670","phase":"PHASE4","title":"Efficacy Study on Cognitive Functions in Schizophrenic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":"Schizophrenia","enrollment":37},{"nctId":"NCT01222923","phase":"NA","title":"Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2004-10","conditions":"Healthy","enrollment":40},{"nctId":"NCT01222975","phase":"NA","title":"Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2004-10","conditions":"Healthy","enrollment":44},{"nctId":"NCT01155921","phase":"PHASE1","title":"Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2004-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT01155934","phase":"PHASE1","title":"Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2004-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT00817648","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2008-12","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT00932529","phase":"PHASE4","title":"Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2003-02","conditions":"Psychotic Disorders","enrollment":226},{"nctId":"NCT00246272","phase":"PHASE3","title":"An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"2004-10","conditions":"Schizophrenia","enrollment":82}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Risperdal"],"phase":"marketed","status":"active","brandName":"Risperidone tablets","genericName":"Risperidone tablets","companyName":"Sumitomo Pharma (Suzhou) Co., Ltd.","companyId":"sumitomo-pharma-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}